Docetaxel injection and Capecitabine tablets combined with Oxaliplatin injection in postoperative chemotherapy for esophageal cancer
10.7507/1007-4848.201607033
- VernacularTitle:多西他赛注射液及卡培他滨片与奥沙利铂注射液联合应用在食管癌术后化疗中的疗效分析
- Author:
DOU Yawei
1
,
2
,
3
;
LV Shanshan
4
,
5
;
TIAN Wei
1
,
2
,
3
;
WANG Hongtao
1
,
2
,
3
;
ZHU Jianfei
1
,
2
,
3
;
DAI Yun
1
,
2
,
3
;
LUO Xianghui
1
,
2
,
3
Author Information
1. Department of Thoracic Surgery, Shaanxi People'
2. s Hospital, Xi&rsquo
3. an, 710068, P.R.China
4. Department of Cardiothoracic Surgery, Xijing Hospital, The Fourth Military Medical University, Xi&rsquo
5. an, 710032, P.R.China
- Publication Type:Journal Article
- Keywords:
Docetaxel;
Capecitabine;
Oxaliplatin;
esophageal cancer
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2017;24(11):853-857
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the efficacy of Docetaxel injection and Capecitabine tablets combined with Oxaliplatin injection in chemotherapy for patients after esophageal cancer surgery. Methods We retrospectively analyzed the clinical data of 101 patients with esophageal cancer who underwent radical surgery from June 2010 to December 2012, including 58 males and 43 females. According to the different treatment methods they were divided into a study group (58 patients, 32 males and 26 females, postoperatively receiving Docetaxel injection, Capecitabine tablets, Oxaliplatin injection and chemotherapy) and a control group (43 patients, 26 males and 17 females, taking Docetaxel injection and Capecitabine tablets for 4 consecutive courses). We compared the difference in the outcomes between the two groups. Results There was no significant difference in the level of serum anticancer antigen (CEA), carbohydrate antigen 125 (CA125), carbohydrate antigen 199 (CA199) and squamous cell carcinoma antigen (SCC) before chemotherapy between two groups (P>0.05). After chemotherapy, the level of serum CEA, CA125, CA199, SCC in the study group was significantly lower than that in the control group (P<0.05). The 1-year survival rate of the study group was 92.59% and the 2-year survival rate was 70.37%, which were not significantly different from those of the control group (P>0.05). The 3-year survival rate of the study group was significantly higher than that of the control group (57.41 % vs. 32.43%, P<0.05). The mean survival time of the study group was longer than that of the control group (31 months vs. 22 months, P=0.001). Conclusion Docetaxel injection and Capecitabine tablets combined with Oxaliplatin injection for the treatment of esophageal cancer surgery can significantly reduce levels of tumor markers in serum after esophageal cancer surgery, and is favorable for the long-term survival of patients, but adverse reactions should be noted.
